Press Releases Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
41.32 ^USD	-2.39%		-4.88%	+168.66%

May. 10	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating	MT
May. 09	Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	May. 09	GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K	May. 09	PU
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 07	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	Apr. 02	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	Apr. 02	AQ
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 20	GL
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 20	AQ
Developing a new treatment paradigm for IgAN	Mar. 14	AQ
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference	Feb. 28	GL
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 02	GL
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock	Feb. 01	GL
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock	Jan. 29	GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock	Jan. 29	GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock	Jan. 29	AQ
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy	Jan. 25	GL
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024	Jan. 08	GL
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer	Jan. 08	GL
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer	Jan. 08	AQ
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024	Jan. 08	AQ
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Press Releases

Filters